Excellent question. There is certainly a need! If we step back and take an honest look at our control rates with SBRT, while primary tumor control rates are high, we suffer the same viciousness of lung cancer that surgeons do - local control is trumped by a 2-3x rate of regional and distant failure....

Only in the setting of a clinical trial. In the standard of care setting, there is no role for adjuvant therapy here.

There is not currently a proven role for systemic therapy in this population, although several randomized trials (such as SWOG/NRG S1914) are currently evaluating this question. Based on the surgical literature, one might expect a benefit to chemotherapy for the sub-group of patients with tumors lar...

SBRT + Atezo trial will be opening soon

Agree with the answers above and with some nuance. Completion of the phase III trials will be decisive in IO benefit in early-stage non-small cell lung cancer (ES-NSCLC). However, it's likely that NGS and IHC will start to pivot in how we individually approach ES-NSCLC treatment after SABR (and surg...